Case Study

Preparing A New Drug Application (NDA) With A CDISC Conversion

Drug development iStock-1067499066

Regulatory submissions are the most critical milestones in clinical research programs. Quality submissions can accelerate time to market, maximize research investments and bring the benefit of new treatments to patients sooner.

In August 2018, when the time came for RedHill Biopharma (Nasdaq: RDHL) to prepare its New Drug Application (NDA) for Talicia® (omeprazole magnesium, amoxicillin and rifabutin), the specialty biopharmaceutical company turned to Bioforum’s team of experts to prepare key components of the regulatory submission. Approved by the FDA for the treatment of H. pylori in adults in November 2019, Talicia® is the only available rifabutin-based therapy that addresses the growing resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies.

VIEW THE CASE STUDY!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader

Bioforum the Data Masters Inc.